Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acacia ends two patent disputes with licence deals

This article was originally published in Clinica

Executive Summary

Electronic technology firm Acacia Research has settled patent litigation suits brought against two of its medtech subsidiaries by signing licensing deals with the plaintiffs. Firstly, Johnson & Johnson has ended a patent dispute over cannulae technology by signing a licence agreement with Acacia’s Cardio Access subsidiary. According to Acacia Research, the disagreement involved cannulae with multiple access port legs and at least one haemostatic valve, which can be adapted for percutaneous insertion of various catheters. In a separate agreement, Acacia’s Hospital Systems subsidiary resolved legal proceedings with medical imaging firm UltraRAD (West Berlin, New Jersey) by entering a licence agreement for a portfolio of patents linked to medical picture archiving and communication technology. Financial terms of the two agreements were not disclosed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel